Vanguard Personalized Indexing Management LLC Invests $33,000 in Alto Neuroscience, Inc. $ANRO

Vanguard Personalized Indexing Management LLC acquired a new stake in shares of Alto Neuroscience, Inc. (NYSE:ANRO) during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 14,990 shares of the company’s stock, valued at approximately $33,000. Vanguard Personalized Indexing Management LLC owned 0.06% of Alto Neuroscience at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. SCS Capital Management LLC bought a new stake in shares of Alto Neuroscience in the 1st quarter worth about $144,000. AQR Capital Management LLC bought a new stake in Alto Neuroscience during the first quarter worth about $52,000. AWM Investment Company Inc. grew its stake in Alto Neuroscience by 31.1% during the first quarter. AWM Investment Company Inc. now owns 901,984 shares of the company’s stock worth $1,948,000 after buying an additional 214,153 shares during the last quarter. Armistice Capital LLC increased its holdings in Alto Neuroscience by 146.2% during the 1st quarter. Armistice Capital LLC now owns 1,600,000 shares of the company’s stock valued at $3,456,000 after purchasing an additional 950,000 shares in the last quarter. Finally, Nuveen LLC acquired a new stake in Alto Neuroscience during the 1st quarter valued at $302,000.

Analyst Upgrades and Downgrades

A number of brokerages have commented on ANRO. Robert W. Baird increased their price objective on Alto Neuroscience from $10.00 to $16.00 and gave the company an “outperform” rating in a research report on Monday, October 20th. HC Wainwright lifted their price objective on Alto Neuroscience from $10.00 to $50.00 and gave the stock a “buy” rating in a research report on Friday. Chardan Capital assumed coverage on Alto Neuroscience in a research report on Monday, September 29th. They issued a “buy” rating and a $15.00 price objective for the company. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Alto Neuroscience in a research report on Wednesday, October 8th. Five equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $19.00.

Alto Neuroscience Stock Performance

NYSE ANRO opened at $12.28 on Tuesday. The firm has a 50-day moving average of $5.21 and a 200-day moving average of $3.51. The company has a debt-to-equity ratio of 0.18, a quick ratio of 18.43 and a current ratio of 18.43. The stock has a market cap of $332.65 million, a PE ratio of -5.14 and a beta of 2.00. Alto Neuroscience, Inc. has a 52-week low of $1.60 and a 52-week high of $12.71.

Alto Neuroscience (NYSE:ANRO) last issued its earnings results on Wednesday, August 13th. The company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.57) by ($0.08). On average, sell-side analysts anticipate that Alto Neuroscience, Inc. will post -2.54 EPS for the current year.

Alto Neuroscience Company Profile

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.